223 81 Lund
Xinnate is a Swedish biotech company developing novel therapies for advanced wound care and surgery. The concepts are based on the peptide, BioC, which is part of our natural defense system and is the first and only drug that both prevents and treats infections and simultaneously reduces harmful excessive inflammation, thereby optimizing healing outcomes, also effective on multi-drug resistant bacteria and fungi. The science behind the concept is groundbreaking and published in among others Nature Communications and Science Translational Medicine.
The first product is the BioC wound gel, a pharmaceutical product initially targeting acute wounds. The wound healing market is big and growing and there is an urgent need for advanced non-antibiotic wound care products with clinically proven efficacy optimizing wound healing in a cost-effective and sustainable way.
In vivo-studies of the BioC wound gel have shown fantastic superior results compared to commercial benchmarks and the plan is now to show clinical safety and proof of concept in the first clinical study 2021. Xinnate is actively seeking co-development partnerships to finalize the development and to commercialise the BioC concepts.